RCS - Immupharma PLC - IMM attending Bio-Europe Spring 17-19 March,Milan

ImmuPharmaAnnouncement

14/03/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250314:nRSN5640Aa&default-theme=true

RNS Number : 5640A  Immupharma PLC  14 March 2025

 
14 March 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

IMMUPHARMA ATTENDING BIO-EUROPE SPRING

 17-19 MARCH 2025, MILAN

 

Further opportunities to present recent insights into the MOA* of the P140
technology platform

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr
Sebastien Goudreau, CEO of the R&D subsidiary ImmuPharma Biotech will be
attending the Bio-Europe Spring Conference from 17-19 March 2025, in Milan.

 

BIO-Europe Spring is a premier partnering event in the biopharmaceutical and
life sciences sector bringing together over 3,700 executives and
facilitating more than 20,000 one-on-one meetings. It is an important
opportunity for networking among biotech companies, pharmaceutical firms,
investors, and academia.

 

Commenting on attendance at the Bio-Europe Spring conference, Tim McCarthy,
CEO of ImmuPharma said: "Following on from positive discussions already held
with a number of global BioPharma companies, we are focussed on continuing the
momentum towards completing commercial deals across the portfolio."

 

 

*Mechanism of Action - update announcement issued on 13 March 2025 |
https://www.immupharma.co.uk/news (https://www.immupharma.co.uk/news)

 

 

Ends

 

 

 

 

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140, is a unique non-immunosuppressive
peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases.

 

 

For additional information about ImmuPharma please visit www.immupharma
(http://www.immupharma) .co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

About Reach announcements

 

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFFSUDEISEID